ArticleJournal of inflammation research2026
Differential Diagnostic Value of Neutrophil Gelatinase-Associated Lipocalin and Cystatin C in Ischemic Stroke Patients with or without Chronic Kidney Disease.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: The similarities in organizational structure and microenvironment between the brain and kidneys suggest the potential utility of kidney biomarkers in the detection of cerebrovascular diseases. Cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL), well-established sensitive biomarkers of kidney injury, may also recognize as indicators of neuroinflammation. However, their diagnostic capabilities for ischemic stroke (IS) attacks under different kidney function states remain unclear. This case-control study aims to evaluate the diagnostic value of serum kidney biomarkers for ischemic stroke (IS) attack, with focus on NGAL and CysC. Methods: A total of 498 patients with first IS attack, 173 patients with risk-related diseases (designated as the disease control [DC] group), and 293 healthy subjects (serving as the healthy control [HC] group) were enrolled. A comprehensive comparative analysis was performed to examine the associations between common kidney biomarkers (Specifically, NGAL and CysC) and IS. Results: Serum NGAL levels were significantly elevated in patients with first IS compared with both the HC group (z=5.964, P<0.001) and the DC group (z=12.191, P<0.001). In contrast, serum CysC levels were significantly higher in these patients relative to the HC group (z=5.762, P<0.001), but no statistically significant difference was observed when compared with the DC group (z=1.663, P=0.289). Partial correlation analysis revealed: 1) among IS patients with normal kidney function, NGAL exhibited the strongest partial correlation with IS (r Conclusion: IS is intricately linked to both kidney injury and neuroinflammation. NGAL and CysC serve as appropriate biomarkers for diagnosing IS attack in patients with normal kidney function and those with CKD, respectively. Respective monitoring of CysC and NGAL in individuals with and without CKD could facilitate early diagnosis, prevention and targeted management of stroke in high-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.